MARKET

CRBP

CRBP

Corbus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.650
+0.110
+7.14%
After Hours: 1.625 -0.025 -1.52% 17:05 05/07 EDT
OPEN
1.540
PREV CLOSE
1.540
HIGH
1.680
LOW
1.540
VOLUME
2.41M
TURNOVER
--
52 WEEK HIGH
9.78
52 WEEK LOW
0.9100
MARKET CAP
206.30M
P/E (TTM)
-1.1236
1D
5D
1M
3M
1Y
5Y
Cannabis Stock Gainers And Losers From May 6, 2021
GAINERS: Rhinomed (OTC: RHNMF) shares closed up 39.34% at $0.17
Benzinga · 1d ago
Corbus Pharmaceuticals Holdings Inc. stock outperforms market on strong trading day
Shares of Corbus Pharmaceuticals Holdings Inc. rallied 1.20% to $1.69 Wednesday, on what proved to be an all-around mixed trading session for the stock...
marketwatch.com · 2d ago
Global Scleroderma Therapeutics Market Trends 2020 | Segmentation, Outlook, Industry Report to 2026
May 05, 2021 (Market Insight Reports) -- The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period...
Market Insight Reports · 2d ago
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors
Shares of Corbus Pharmaceuticals Holdings Inc. shed 4.44% to $1.72 Monday, on what proved to be an all-around mixed trading session for the stock market,...
marketwatch.com · 4d ago
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks.com · 4d ago
Cannabis Stock Gainers And Losers From April 30, 2021
GAINERS: Rhinomed (OTC: RHNMF) shares closed up 106% at $0.10
Benzinga · 6d ago
Corbus Pharmaceuticals Holdings Inc. stock falls Friday, underperforms market
Shares of Corbus Pharmaceuticals Holdings Inc. slid 4.76% to $1.80 Friday, on what proved to be an all-around grim trading session for the stock market, with...
marketwatch.com · 04/30 20:46
Scleroderma Therapeutics Market Size, Share, Trends, Analysis and Forecast 2027
Apr 30, 2021 (Market Insight Reports) -- The Global Scleroderma Therapeutics Market is poised to register a CAGR of over 6% during the forecast period 2020...
Market Insight Reports · 04/30 14:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRBP. Analyze the recent business situations of Corbus Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRBP stock price target is 2.228 with a high estimate of 3.000 and a low estimate of 1.790.
EPS
Institutional Holdings
Institutions: 187
Institutional Holdings: 40.69M
% Owned: 32.54%
Shares Outstanding: 125.03M
TypeInstitutionsShares
Increased
21
7.24M
New
22
816.85K
Decreased
42
20.84M
Sold Out
35
4.32M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
Alan Holmer
Chief Executive Officer/Director
Yuval Cohen
Chief Financial Officer
Sean Moran
Other
Craig Millian
Executive Director
Sergei Atamas
Other
Barbara White
Independent Director
Avery Catlin
Independent Director
Rachelle Jacques
Independent Director
John Jenkins
Independent Director
Peter Salzmann
No Data
  • All
  • Financials
  • Insiders
More
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Webull offers kinds of Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ:CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.